What is IGF-1 LR3?
IGF-1 LR3 is a modified IGF-1 analogue. A rat experiment assessed intestinal tissue growth and glucose-analogue absorption, rather than bodybuilding outcomes.
Biological role or research focus
Intestinal growth and absorption models.
The normalization matters: more tissue is different from greater function per unit of tissue. No human strength or athletic benefit was tested.
Names you may encounter
Long R3 IGF-1 · LR3 IGF-1
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Modified long-R3 IGF-1 analogue
- Research focus
- Intestinal growth and absorption models
- Featured evidence
- Animal study
- Source check
- October 4, 2026
Quick answers
- Is IGF-1 LR3 FDA approved?
- No. No FDA-approved drug contains IGF-1 LR3. Source ↗
- Is IGF-1 LR3 safe?
- IGF-1 LR3 is an unapproved, modified IGF-1 with no human safety studies. In fetal sheep it suppressed insulin secretion during infusion. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is IGF-1 LR3 banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S2.3 Growth factors and growth factor modulators). Source ↗
- Has the FDA taken action over IGF-1 LR3?
- Yes. Our records list 1 FDA action naming it, most recently on April 1, 2020: FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing IGF1-LR3 among bulk substances that are not eligible for 503A compounding exemptions. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Long-R3 IGF-1 and rat intestinal absorption (2002) | Animal study | Rats receiving seven-day experimental infusions. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Animal study · 2002
Long-R3 IGF-1 and rat intestinal absorption
What did this publication test, and what did it find?
- Population / model
- Rats receiving seven-day experimental infusions.
- Study design
- Comparison of native IGF-1, long-R3 IGF-1, and vehicle, followed by jejunal tissue and absorption measurements.
- Main finding
- Mucosal mass and absorption per length of intestine increased. The absorption difference was no longer significant when expressed relative to tissue weight.
- Limits & context
- The normalization matters: more tissue is different from greater function per unit of tissue. No human strength or athletic benefit was tested.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming IGF-1 LR3 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep. ↗
American journal of physiology. Endocrinology and metabolism · 2025 Jan 1 · Journal Article
Read available full text ↗
Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. ↗
Applied microbiology and biotechnology · 2023 Jul · Journal Article
Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. ↗
Journal of developmental origins of health and disease · 2023 Jun · Journal Article, Research Support, N.I.H., Extramural
Read available full text ↗
Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration. ↗
International journal of biological macromolecules · 2025 Nov · Journal Article
Risks & interactions
IGF-1 LR3 is an unapproved, modified IGF-1 with no human safety studies. In fetal sheep it suppressed insulin secretion during infusion.
No published human studies were found. Animal work is mostly short infusion experiments. The approved IGF-1 medicine mecasermin is a different molecule.
Unassessed: no human safety data
Warning signs in animal or lab studies: Diabetes or blood-sugar medicines
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Harms seen in animal or lab studies
- Lowered insulin levels and glucose-stimulated insulin secretion during infusion in fetal sheep
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: IGF-1 LR3 infusion and insulin secretion in fetal sheep (2023) ↗ · IGF-1 LR3 in growth-restricted fetal sheep (2025) ↗ · Long-R3-IGF-I and intestinal absorption in rats (2002) ↗
Safety & what remains unknown
A short animal infusion experiment cannot establish safety for human metabolic or tissue-growth effects.
Evidence boundaries
The normalization matters: more tissue is different from greater function per unit of tissue. No human strength or athletic benefit was tested.
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not found on FDA's 503A category 1, 2 or 3 lists (updated May 14, 2026) or the category 2 safety-risk page (updated April 22, 2026). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S2.3 Growth factors and growth factor modulators
Not named, but S2.3 prohibits "IGF-1 and its analogues" (likely covered). source
FDA actions
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing IGF1-LR3 among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
Other notes
- The FDA-approved IGF-1 drug is mecasermin (Increlex, BLA 021839), a different molecule from IGF-1 LR3. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This page distinguishes LR3 from DES and native IGF-1. Different analogues cannot inherit each other’s effects or safety findings.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
The study examined tissue responses to growth-factor exposure. Larger tissue mass can change total absorption without improving absorption per unit of tissue.
Questions worth asking
- Did the study show better absorption per unit of tissue?
- What material, population, and route were actually studied?
- The normalization matters: more tissue is different from greater function per unit of tissue. No human strength or athletic benefit was tested.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did the study show better absorption per unit of tissue?
The reported difference lost significance when normalized to tissue weight. The main observation included increased mucosal mass.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
